Skip to content
Medical Health Aged Care

Dementia and palliative care – meeting the need in Australia’s future

Palliative Care Australia 2 mins read

Palliative Care Australia and Dementia Australia have framed nine recommendations to deliver better quality of life to people, families, and carers travelling life’s journey with dementia. 

“Dementia is the biggest health issue facing Australians over 65 years,” says Camilla Rowland, Chief Executive Officer, Palliative Care Australia (PCA).  

“We need to better integrate dementia care and palliative care so that the 400,000 Australians currently living with dementia can make the most of life - and for a lot of those people, that will mean many years of quality living and relationships.” 

To that end PCA and Dementia Australia, have just updated a long-standing joint policy statement as part of ongoing advocacy efforts in the face of increasing demand for care. 

Demand for palliative care is increasing, we are on a trajectory towards a 50% increase in the next decade and the need doubling by 2050,” Ms Rowland says.  

“The growing number of Australians with dementia is a key driver, the Australian Institute of Health and Welfare (AIHW) report that the number of people with dementia is expected to increase to more than 800,000 by 2058. 

“Central to meeting that need is having a workforce that is trained and available,” Ms Rowland says. 

 The joint policy statement speaks to that and makes nine recommendations including: 

  • Compulsory dementia and palliative care education for all health and care professionals involved in the delivery of care for people living with dementia. 

  • Early involvement of the person with dementia, and their family members and carers, in discussions about palliative care. 

  • Flexible models of palliative care which enable health and care professionals to provide the right care, at the right time and in the right setting to accommodate the changing needs of people living with dementia, and their carers. 

  • Improved access to specialist palliative care services in the community to address the complex needs of people living with dementia and their carers, and to enable greater choice in the type of care that is provided. 

  • The implementation of nationally consistent advance care planning legislation to reduce jurisdictional confusion. 

  • Encourage individuals to link advance care plans to their My Health Record to ensure they can be accessed by all health professionals involved in the care of the individual in a timely manner. 

Dementia Australia CEO Maree McCabe says, “dementia is a terminal illness and appropriate palliative care is an essential element of quality care for people with dementia, and for their families and carers.”  

 “While we acknowledge the contextual complexities of dementia care within the different health care and community settings, it is essential that streamlined services are developed and accessible for more effective home and community palliative care experiences. 

 “Improving palliative care for people with dementia, no matter where they live, must be a policy priority, Australia-wide, across the states and territories.” 

 The full joint policy statement is available on the Palliative Care Australia website. 

“We look forward to the continued interest of Minister Butler in this work, the reform agenda he and Minister Wells and Assistant Minister Kearney are leading is a foundation for the change we want to see, but more needs to be done and we are ready to play our part,” Ms Rowland says. 


Contact details:

Ian Campbell

P: 0417 482 171

E: [email protected]

More from this category

  • Medical Health Aged Care
  • 08/12/2025
  • 10:11
BeOne Medicines Ltd.

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL Sonrotoclax in combination with BRUKINSA demonstrated rapid…

  • Contains:
  • Medical Health Aged Care
  • 08/12/2025
  • 09:40
Miltenyi Biomedicine

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease featuresA 12-day manufacturing time resulted in a vein-to-vein time of 14-16 days, reducing the likelihood for bridging therapy.BERGISCH GLADBACH, Germany, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Miltenyi Biomedicine today announced results from the pivotal DALY 2-EU trial evaluating the efficacy and safety of zamtocabtagene autoleucel (zamto-cel) compared with standard chemoimmunotherapy (R-GemOx or Pola-BR) in patients with…

  • Medical Health Aged Care, Seniors Interest
  • 08/12/2025
  • 08:56
Monash University

Men and women may need different medications to avoid broken bones

A new international study, published in Osteoporosis International and led by Monash’s Centre for Medicine Use and Safety (CMUS), investigated the risks of a…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.